Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.

Front Immunol · 2022 · PMC9498063 · PMID 36159789

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Combination therapy also reduced risk of death by 20% and improved OS rates versus nivolumab, although it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.